AR inhibition remains the mainstay treatment for metastatic prostate cancer, a practice grounded in seminal experiments from 1941, which demonstrated the androgen-driven and androgen-dependent nature of prostate cancer [37]. The gene discussed is AR; the disease is prostate carcinoma.